You are here
European Union Approves Docetaxel in Prostate Cancer
The Commission approval is based on the results of a large landmark phase III clinical trial, TAX 327, which demonstrated that a Taxotere-based regimen significantly reduced the risk of death by 24 percent in men with androgen- independent (hormone-refractory) metastatic prostate cancer. Investigators in the TAX 327 trial also reported that Taxotere significantly improved patients' Prostate Specific Antigen (PSA) response by 43 percent and improved pain response by 59 percent, relative to mitoxantrone.
In the TAX 327 trial, investigators reported that Taxotere was well tolerated. The most commonly observed adverse events in TAX 327 were alopecia, fatigue and nausea. Grade 3-4 neutropenia was reported more frequently in the Taxotere group than the mitoxantrone group (32 percent vs 21.7 percent, p=0.004).
The results of this pivotal study were presented in June 2004 at the American Society of Clinical Oncology meeting (ASCO). On May 19, 2004, the U.S. Food and Drug Administration granted Taxotere approval for use in combination with prednisone as a treatment for men with hormone-refractory metastatic prostate cancer.
"Finally, we can offer our patients an effective chemotherapy for prostate cancer. The pivotal results of the TAX 327 study not only demonstrated a significant survival improvement, but also a significant improvement in the quality of life and improved pain response of patients, even during their chemotherapy," said Ronald de Wit, MD, PhD, lead European Investigator for TAX 327, Associate Professor, Senior Staff Medical Oncologist, Erasmus University Medical Center, Rotterdam, the Netherlands, and service Chief of Medical Oncology, Rotterdam Cancer Institute.
This European approval marks yet another important milestone for Taxotere and underscores sanofi-aventis commitment to positively impact the life of men with this disease. In addition, this action makes Taxotere the only drug approved for breast, lung and prostate cancer, three of the most prevalent cancers in the world today.
About Prostate Cancer
Prostate cancer ranks third worldwide in cancer incidence and sixth in cancer mortality among men. In the United States, more than 230,000 American men will be diagnosed with prostate cancer this year, and 30,000 will die of the disease. In the European Union, 138,000 new cases will be diagnosed, and 45,000 patients will die of the disease.
Current therapy for advanced prostate cancer is hormonal manipulation (i.e., blockage of androgen hormones like testosterone that would otherwise stimulate the growth of prostate cancer cells). However, the effects of this treatment typically last between 24 and 36 months, at which time patients may become refractory to hormonal therapy and be considered candidates for chemotherapy, such as Taxotere.
Taxotere, a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially "freezing" the cell's internal skeleton, which is comprised of microtubules. Microtubules assemble and disassemble during a cell cycle. Taxotere promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing and resulting in cancer cell death.
Taxotere is indicated for treatment of metastatic breast cancer and non- small cell lung cancer, and is being studied extensively in clinical trials for safety and efficacy in early-stage breast and gastric cancers. On August 18, 2004, the FDA approved Taxotere® for use in combination with doxorubicin and cyclophosphamide (TAC regimen) for the adjuvant (post surgery) treatment of patients with operable, node-positive breast cancer.
In 2003, Taxotere generated worldwide sales of over 1.3 billion euros.
Source: sanofi-aventis Group